MEDIMMUNE
MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.
MEDIMMUNE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1987-01-01
Address:
Maryland, Louisiana, United States
Country:
United States
Website Url:
http://www.astrazeneca.com
Total Employee:
5001+
Status:
Active
Contact:
301-398-0000
Technology used in webpage:
WordPress Wordpress Plugins IPv6 Microsoft Azure DNS PHP Amazon Route 53 Microsoft Japanese Yen Mimecast GlobalSign Domain Verification
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Bionorica SE
Bionorica SE develops and manufactures herbal medicines for customers worldwide.
Encysive Pharmaceuticals
Encysive Pharmaceuticals develops synthetic and small molecule compounds to address medical needs worldwide.
Hyland's
Hyland’s, Inc., a division of Standard Homeopathic Company.
ILEX Oncology,Inc.
ILEX is a drug development company focused exclusively on oncology.
Leica Biosystems
Leica Biosystems develops laboratory workflow solutions for anatomic pathology involved in the advancement of cancer diagnostics.
Nexien BioPharma
Nexien BioPharma develops cannabinoid based medications for specific medical conditions and disorders.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Sunlight
Sunlight develops technology that improves people's working lives.
Viramatix
We develop therapeutics for viral diseases of unmet medical need.
Current Employees Featured
Rakesh Dixit Vice President, R & D, Global Head, Biologics Safety Assessment @ MedImmune
Vice President, R & D, Global Head, Biologics Safety Assessment
Ed Mathers Executive Vice President, Corporate Development and Venture @ MedImmune
Executive Vice President, Corporate Development and Venture
Frank J. Malinoski Team Member @ MedImmune
Team Member
Cristina Rondinone Senior Vice President, Head Of Cardiovascular, Renal and Metabolic Diseases @ MedImmune
Senior Vice President, Head Of Cardiovascular, Renal and Metabolic Diseases
2019-01-01
Jhi Zhu Senior Scientist @ MedImmune
Senior Scientist
James Brown Director, IT Relationship Management, R&D @ MedImmune
Director, IT Relationship Management, R&D
2007-05-01
Michael Dittmer Associate Scientist, BioProcess Engineering @ MedImmune
Associate Scientist, BioProcess Engineering
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-11-04 | Definiens | Definiens acquired by MedImmune | 150 M USD |
| 2014-09-19 | Allozyne | Allozyne acquired by MedImmune | 5.5 M USD |
| 2013-10-15 | Spirogen | Spirogen acquired by MedImmune | 440 M USD |
| 2013-08-27 | Amplimmune | Amplimmune acquired by MedImmune | 500 M USD |
| 2013-04-03 | AlphaCore Pharma | AlphaCore Pharma acquired by MedImmune | N/A |
| 2005-09-15 | Cellective Therapeutics | Cellective Therapeutics acquired by MedImmune | 160 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-04-25 | Corvidia | MedImmune investment in Series B - Corvidia | 60 M USD |
| 2014-11-10 | MdBio Foundation | MedImmune investment in Grant - MdBio Foundation | 500 K USD |
| 2013-10-16 | ADC Therapeutics | MedImmune investment in Series B - ADC Therapeutics | 40 M USD |
Official Site Inspections
http://www.astrazeneca.com Semrush global rank: 3.13 M Semrush visits lastest month: 1.69 K
- Host name: ac9efcde36061855b.awsglobalaccelerator.com
- IP address: 15.197.255.153
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MedImmune"
About Our Company - AstraZeneca
We are a global, science-led, patient-focused biopharmaceutical company, creating innovative medicines for millions of patients worldwide.See details»
AstraZeneca - Research-Based BioPharmaceutical Company
We are transforming the future of healthcare by unlocking the power of what science can do, for people, society and planet. Our company has continued on its strong growth trajectory in the …See details»
AstraZeneca Canada
This website is intended for people seeking information on AstraZeneca's worldwide business. We also have country sites; click the 'Global sites' link for the directory.See details»
Leadership - Our Company - AstraZeneca
Requesting Support − Sponsorships, Grants & Donations
AstraZeneca aims to support organizations and initiatives that advance patient health, increase access to care, drive science innovation, and build resilient communities.See details»
AstraZeneca - Wikipedia
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in …See details»
AstraZeneca | World Economic Forum
Feb 28, 2023 · AstraZeneca is a global, science-led biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative medicines and improving access to them. Its therapy areas cover oncology, …See details»
AstraZeneca - The Org
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.See details»
Values and Behaviours - AstraZeneca
Our values guide how we work together and are integral in defining who we are as a business and team. They lead our decision making, detail our beliefs and foster our unique culture. Our behaviours underpin our values and help us …See details»
Org Chart AstraZeneca - The Official Board
The organizational chart of AstraZeneca displays its 416 main executives including Pascal Soriot, Aradhana Sarin, Marc Dunoyer and Helen MacPhee Toggle navigation The Official Board SearchSee details»
AstraZeneca Case Study | PMI - Project Management …
Aug 1, 2021 · AstraZeneca is a global bio-pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020). As of July 2021, AstraZeneca has released 1 billion doses for supply to 170 …See details»
Injectable asthma treatment hailed as ‘game-changer.’ Here’s why
5 hours ago · Fasenra is AstraZeneca’s second-best selling drug from its respiratory and immunology portfolio. It brought in $436 million in sales in the third quarter, up 13% from a …See details»
AstraZeneca - Crunchbase Company Profile & Funding
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. AstraZeneca reported a positive financial trend by setting a revenue …See details»
AstraZeneca announces organisational changes
Jan 7, 2019 · AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company …See details»
Oxford–AstraZeneca COVID-19 vaccine - Wikipedia
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19.See details»
AstraZeneca's COVID-19 vaccine and seniors: Where Canada and …
Mar 3, 2021 · Canada is set to receive 1.9 million doses of the AstraZeneca-Oxford vaccine through the COVAX program by the end of June. The government has also ordered 20 million …See details»
The Oxford/AstraZeneca COVID-19 vaccine: what you need to know
Apr 19, 2021 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine …See details»
The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) …
Jun 13, 2022 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine …See details»
Vaccine-Induced Prothrombotic Immune Thrombocytopenia …
Apr 2, 2021 · The AstraZeneca COVID-19 vaccine appears to be associated with autoimmune thrombosis that mimics heparin-induced thrombocytopenia (HIT). The United Kingdom, …See details»
China Puts Trump, Trade, and Foreign Business in the Crosshairs
Nov 21, 2024 · AstraZeneca confirmed this month that Chinese investigators had detained Leon Wang, president of the company's China business. Wang is the subject of a corruption probe.See details»